- Peter Wrighton-Smith, PhD, Chief Executive Officer
- Peter Edwardson, PhD, Chief Scientific Officer
- Jeff Schroeder, President, North America
- Simon Turner, Vice President, Finance and Administration
- Jon Watts, Vice President, Business Development
- Patricia Randall, Vice President and General Counsel
Peter Wrighton-Smith, PhD
Chief Executive Officer
Dr. Wrighton-Smith started Oxford Immunotec after having spent 5 years at PowderJect Pharmaceuticals PLC, now part of Chiron Corporation. During his time there, he saw PowderJect grow to a global vaccines business with over 1,000 employees and immediately prior to founding Oxford Immunotec, he was Special Projects Director at PowderJect. Prior to that, he was Managing Director of PowderJect Diagnostics Ltd, a subsidiary of PowderJect, developing cellular immune based diagnostics. He has also held scientific, business development & project management roles at major companies in both the healthcare and engineering fields, including posts in Switzerland and California. Peter has a Masters in Engineering, Economics & Management, and a DPhil in Medical Engineering both from Oxford University.
Peter Edwardson, PhD
Chief Scientific Officer
Dr. Edwardson has over 20 years experience in the medical device industry in both small start-up companies and large corporations. Most recently, Peter was VP of Medical Technologies, Prometic Biosciences Ltd., where he led a joint venture with the American Red Cross to develop products to remove pathogens from blood. Prior to this, he was Technical Director at Tayside Flow Technologies and Tissuemed Ltd, start-up companies focused on development and commercialization of implantable devices. Peter is author of numerous scientific publications and international patents and has a PhD from Cambridge University.
President, North America
Mr. Schroeder has over 20 years experience in the diagnostics business. Prior to joining Oxford Immunotec, he served as Vice-President of Marketing at Cytyc Corporation where he led the product marketing team to develop and execute the strategic plan for the ThinPrep Pap Test and ThinPrep Imaging System. Subsequently at Cytyc he ran a newly-acquired sales team to achieve sales targets for the MammoSite Radiation Therapy System, a device for breast cancer radiation therapy used by breast surgeons and radiation oncologists. Prior to Cytyc, he managed sales, marketing and customer service for CytoLogix Corporation, a venture funded cellular diagnostics company in Cambridge, Massachusetts. Jeff previously spent 16 years in sales and marketing positions in medical diagnostics at Abbott Laboratories.
Vice President, Finance and Administration
Mr. Turner joined Oxford Immunotec after having spent six years in major merchant banks, including JP Morgan and Deutsche Bank where he was responsible for trading programs in fixed income, metals and derivatives sectors. Most recently he was VP Strategic Initiatives for Bank of America. Simon originally trained in chemical engineering, before joining the accountancy firm Binder Hamlyn where he qualified as an accountant before entering the banking industry. Simon is a Chartered Accountant and has a Masters in Finance from London Business School.
Vice President, Business Development
Mr. Watts has more than 25 years’ experience in sales, marketing and business development in the pharmaceutical, diagnostic and biotechnology sectors. During his career in the industry Jon served in increasingly senior positions with Astra, Becton Dickinson and RP Scherer and was Director of Business Development at Cortecs Plc prior to joining PowderJect Plc where he served as VP of Business Development. He founded Medborough Ltd a business development consultancy in 2003 whose client list includes major corporations, biotech start ups and marketing companies. Jon joined Oxford Immunotec in February 2007.
Vice President and General Counsel
Ms. Randall has more than thirty years experience as a lawyer and advisor to both public and private companies in a wide range of industries. Most recently, she served as vice president, general counsel and secretary of Matritech, Inc. (AMEX:MZT), a biotechnology company specializing in proteomic diagnostic products for the early detection of a variety of cancers. Previously, she served as vice president and general counsel of Hadco Corporation (NYSE:HDC), a global manufacturer of printed circuit boards, and as vice president and general counsel of Robotic Vision Systems, Inc. (NASD: ROBV), a leading supplier of machine vision technologies. Pat also serves on the board of directors of Belmont Instrument Corporation, a private medical device company.